These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26552746)

  • 1. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
    Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
    Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
    Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
    J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model.
    Wilson AJ; Barham W; Saskowski J; Tikhomirov O; Chen L; Lee HJ; Yull F; Khabele D
    J Ovarian Res; 2013 Sep; 6(1):63. PubMed ID: 24020521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer.
    Hoover AA; Hufnagel DH; Harris W; Bullock K; Glass EB; Liu E; Barham W; Crispens MA; Khabele D; Giorgio TD; Wilson AJ; Yull FE
    BMC Cancer; 2020 Oct; 20(1):970. PubMed ID: 33028251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
    Glass EB; Hoover AA; Bullock KK; Madden MZ; Reinfeld BI; Harris W; Parker D; Hufnagel DH; Crispens MA; Khabele D; Rathmell WK; Rathmell JC; Wilson AJ; Giorgio TD; Yull FE
    BMC Cancer; 2022 May; 22(1):497. PubMed ID: 35513776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of thymoquinone as a remedy for polycystic ovary in rat.
    Arif M; Thakur SC; Datta K
    Pharm Biol; 2016; 54(4):674-85. PubMed ID: 26510692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
    Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
    PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.
    Jafri SH; Glass J; Shi R; Zhang S; Prince M; Kleiner-Hancock H
    J Exp Clin Cancer Res; 2010 Jul; 29(1):87. PubMed ID: 20594324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
    Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
    Front Immunol; 2019; 10():1273. PubMed ID: 31214202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression.
    Prat M; Coulson K; Blot C; Jacquemin G; Romano M; Renoud ML; AlaEddine M; Le Naour A; Authier H; Rahabi MC; Benmoussa K; Salon M; Parny M; Delord JP; Ferron G; Lefèvre L; Couderc B; Coste A
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NF-κB activation.
    Cho U; Kim B; Kim S; Han Y; Song YS
    Mol Carcinog; 2018 Feb; 57(2):235-242. PubMed ID: 29024042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of M2-like macrophages in the progression of ovarian cancer.
    Baek SH; Lee HW; Gangadaran P; Oh JM; Zhu L; Rajendran RL; Lee J; Ahn BC
    Exp Cell Res; 2020 Oct; 395(2):112211. PubMed ID: 32755554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-κB pathway.
    Peng L; Liu A; Shen Y; Xu HZ; Yang SZ; Ying XZ; Liao W; Liu HX; Lin ZQ; Chen QY; Cheng SW; Shen WD
    Oncol Rep; 2013 Feb; 29(2):571-8. PubMed ID: 23232982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of NF-κB in the anti-tumor effect of thymoquinone on bladder cancer].
    Mu HQ; Yang S; Wang YJ; Chen YH
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):392-6. PubMed ID: 22490899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-lipoic acid modulates ovarian surface epithelial cell growth.
    Vig-Varga E; Benson EA; Limbil TL; Allison BM; Goebl MG; Harrington MA
    Gynecol Oncol; 2006 Oct; 103(1):45-52. PubMed ID: 16574204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymoquinone attenuates proinflammatory responses in lipopolysaccharide-activated mast cells by modulating NF-kappaB nuclear transactivation.
    El Gazzar MA; El Mezayen R; Nicolls MR; Dreskin SC
    Biochim Biophys Acta; 2007 Apr; 1770(4):556-64. PubMed ID: 17292554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis.
    Sethi G; Ahn KS; Aggarwal BB
    Mol Cancer Res; 2008 Jun; 6(6):1059-70. PubMed ID: 18567808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer.
    Şakalar Ç; İzgi K; İskender B; Sezen S; Aksu H; Çakır M; Kurt B; Turan A; Canatan H
    Tumour Biol; 2016 Apr; 37(4):4467-77. PubMed ID: 26500095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-κB and TGF-β2 signaling.
    Lin SC; Liao YC; Chen PM; Yang YY; Wang YH; Tung SL; Chuang CM; Sung YW; Jang TH; Chuang SE; Wang LH
    J Biomed Sci; 2022 Dec; 29(1):109. PubMed ID: 36550569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
    Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
    Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.